Clinical Trial Update: Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab plus stereotactic body radiotherapy in II-III line metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Stereotactic Body Radiotherapy
• nivolumab (nivolumab)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Renal Cancer Metastatic | Phase 2 | Status: COMPLETED